Digging deeper for new targets in bevacizumab resistance

Neuro Oncol. 2023 Feb 14;25(2):261-262. doi: 10.1093/neuonc/noac269.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Bevacizumab / pharmacology
  • Bevacizumab / therapeutic use
  • Humans
  • Neoplasms* / drug therapy
  • Phosphofructokinase-1*
  • Phosphorylation

Substances

  • Bevacizumab
  • Phosphofructokinase-1